GlaxoSmithKline (GSK), one of the world’s leading research-based pharmaceutical and healthcare companies, and Prosensa, a Dutch biotechnology company, have reported that GSK’s phase III clinical study of drisapersen, an investigational anti-sense oligonucleotide, for the treatment of Duchenne Muscular Dystrophy (DMD) patients with an amenable mutation, did not meet the primary endpoint of a statistically significant improvement in the 6 Minute Walking Distance (6MWD) test compared to placebo.
To read full news, visit:
http://pharmabiz.com/NewsDetails.aspx?aid=77785&sid=2
References:
http://pharmabiz.com/